Trial Profile
Open-label safety and dose conversion/determination study of OROS oxybutynin chloride for urge urinary incontinence
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2007
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Urge incontinence
- Focus Adverse reactions
- Sponsors ALZA Corporation
- 24 Nov 2006 New trial record.